Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 11/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433320 | 1.00 | ACSS2 (0.57) | ACSS2FGFR3KDRABL1MAPT | |
| SCHEMBL27281705 | 0.92 | ACSS2 (0.58) | ACSS2FGFR3KDRABL1GAA | |
| SCHEMBL29433408 | 0.92 | ACSS2 (0.58) | ACSS2FGFR3KDRABL1GAA | |
| SCHEMBL21294542 | 0.92 | ACSS2 (0.58) | ACSS2FGFR3KDRABL1GAA | |
| SCHEMBL21305756 | 0.91 | ACSS2 (0.53) | ACSS2FGFR3KDRABL1FYN | |
| SCHEMBL27281961 | 0.91 | ACSS2 (0.53) | ACSS2FGFR3KDRABL1FYN | |
| SCHEMBL29433424 | 0.89 | ACSS2 (0.60) | ACSS2MAPT | |
| SCHEMBL21294468 | 0.89 | ACSS2 (0.60) | ACSS2MAPT | |
| SCHEMBL21305668 | 0.87 | ACSS2 (0.67) | ACSS2ABL1MAPTFYNBRAF | |
| SCHEMBL21294438 | 0.84 | ACSS2 (0.57) | ACSS2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008025-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | METABOMED LTD. (IL) | 2020-12-01 | — | — | US | disclosed |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | METABOMED LTD. (IL) | 2020-12-01 | — | — | US | disclosed |
| CN-111566092-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2019-08-29 | — | — | US | disclosed |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | ACSS2 1/4885FGFR3 2149/4885KDR 4457/4885 |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ACSS2 1/4885FGFR3 2149/4885KDR 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.